Status:
COMPLETED
A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.
Lead Sponsor:
Pfizer
Conditions:
Migraine
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to collect information of the US users from the Migraine Buddy app between 20 October 2023 and 20 May 2024. Patients who used Nurtec and/or triptans as an acute treatment ...
Detailed Description
This study will utilize retrospective data collected with the Migraine Buddy Mobile application to evaluate satisfaction of treatment with rimegepant and triptans. The study population for this study ...
Eligibility Criteria
Inclusion
- Patients who used Nurtec and/or triptans as an acute treatment for migraine, with or without a background of preventive treatment (anti-CGRP, Botox or oral migraine preventive medications).
- Male or female participants with migraine
- Having consented to the anonymous use of their data for research
- Currently using Nurtec and/or triptans to treat migraine attacks
Exclusion
- Users who did not report using either medication for which they complete the survey within 60 days prior to the survey.
Key Trial Info
Start Date :
June 9 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 10 2024
Estimated Enrollment :
1536 Patients enrolled
Trial Details
Trial ID
NCT06532357
Start Date
June 9 2024
End Date
June 10 2024
Last Update
August 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer
New York, New York, United States, 10001